Business Context and Reporting Period
This Form 8-K filing by Autonomix Medical, Inc. (AMIX) is dated June 18, 2026. The report details the execution of a 1-for-21 reverse stock split of the Company's common stock, authorized by stockholders at the annual meeting on October 30, 2025. The split became effective at 12:01 a.m. Eastern Time on June 24, 2026.
Key Financial Metrics
The filing does not provide current revenue, cash flow, or liquidity data. It focuses on capital structure adjustments and historical loss data retroactively adjusted for the split.
- Outstanding Shares: Reduced from 11,409,344 to approximately 542,000 shares.
- Authorized Shares: Remained at 500 million shares.
- Net Loss (Year Ended March 31, 2026): $16,715,000 (unchanged in total).
- Net Loss Per Share (Post-Split, 2026): $48.80 (basic and diluted).
- Weighted Average Shares Outstanding (Post-Split, 2026): 342,539.
Material Changes Versus Prior Period
The primary material change is the reduction in share count and the corresponding increase in per-share metrics due to the 1-for-21 reverse stock split.
- Share Count: Outstanding shares decreased by approximately 95.6%.
- Per Share Loss: The reported net loss per share for the year ended March 31, 2026, increased from $2.32 (pre-split) to $48.80 (post-split) due to the retroactive adjustment.
- Historical Comparison: The net loss for the year ended March 31, 2025, was $11,410,000, which retroactively adjusts to a post-split loss per share of $137.44.
Guidance, Outlook, and Unusual Items
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future operations. The document addresses specific corporate actions and adjustments:
- Fractional Shares: No fractional shares will be issued; stockholders entitled to fractions will receive cash in lieu thereof based on the average closing price of the five trading days preceding the split.
- Equity Adjustments: Exercise prices and share counts for outstanding stock options and warrants have been proportionately adjusted.
- Trading Status: Common stock resumed trading on The Nasdaq Capital Market on June 24, 2026, under the ticker "AMIX" with a new CUSIP number (05330T304).
Important Facts for Investor Verification
- Verify the new CUSIP number (05330T304) for trading purposes.
- Confirm the cash payment amount for fractional shares, which depends on the average closing price of the five days prior to June 24, 2026.
- Review the adjusted exercise prices and share counts for any held stock options or warrants.
- Note that the Company remains an emerging growth company.
- Understand that the increase in net loss per share is a mathematical result of the split and does not reflect a change in the total dollar amount of the loss.